Portfolio at a glance
Securities as at September 30, 2022
|
Company |
|
Number of securities |
|
Change since 31.12.2021 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Ionis Pharmaceuticals |
|
9 230 000 |
|
(1 002 973) |
|
USD |
|
44.23 |
|
402.9 |
|
13.3% |
|
14.8% |
|
6.5% |
|
Argenx SE |
|
892 503 |
|
(78 035) |
|
USD |
|
353.05 |
|
311.0 |
|
10.3% |
|
11.4% |
|
1.6% |
|
Neurocrine Biosciences |
|
2 798 437 |
|
(216 963) |
|
USD |
|
106.21 |
|
293.4 |
|
9.7% |
|
10.8% |
|
2.9% |
|
Vertex Pharmaceuticals |
|
950 523 |
|
(79 477) |
|
USD |
|
289.54 |
|
271.6 |
|
9.0% |
|
10.0% |
|
0.4% |
|
Alnylam Pharmaceuticals |
|
920 000 |
|
(190 000) |
|
USD |
|
200.16 |
|
181.8 |
|
6.0% |
|
6.7% |
|
0.8% |
|
Incyte |
|
2 691 077 |
|
(205 923) |
|
USD |
|
66.64 |
|
177.0 |
|
5.9% |
|
6.5% |
|
1.2% |
|
Moderna |
|
1 501 951 |
|
(161 398) |
|
USD |
|
118.25 |
|
175.3 |
|
5.8% |
|
6.4% |
|
0.4% |
|
Intra-Cellular Therapies |
|
3 291 479 |
|
(246 940) |
|
USD |
|
46.53 |
|
151.2 |
|
5.0% |
|
5.6% |
|
3.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sage Therapeutics |
|
2 950 278 |
|
(219 826) |
|
USD |
|
39.16 |
|
114.0 |
|
3.8% |
|
4.2% |
|
5.0% |
|
Agios Pharmaceuticals |
|
4 030 792 |
|
(281 500) |
|
USD |
|
28.28 |
|
112.5 |
|
3.7% |
|
4.1% |
|
7.4% |
|
Myovant Sciences |
|
5 872 639 |
|
(249 400) |
|
USD |
|
17.96 |
|
104.1 |
|
3.4% |
|
3.8% |
|
6.1% |
|
Arvinas |
|
2 136 412 |
|
(40 491) |
|
USD |
|
44.49 |
|
93.8 |
|
3.1% |
|
3.4% |
|
4.0% |
|
Relay Therapeutics |
|
4 120 720 |
|
34 758 |
|
USD |
|
22.37 |
|
91.0 |
|
3.0% |
|
3.3% |
|
3.4% |
|
Revolution Medicines |
|
4 602 562 |
|
1 181 100 |
|
USD |
|
19.72 |
|
89.6 |
|
3.0% |
|
3.3% |
|
5.2% |
|
Fate Therapeutics |
|
3 658 536 |
|
(42 800) |
|
USD |
|
22.41 |
|
80.9 |
|
2.7% |
|
3.0% |
|
3.8% |
|
Crispr Therapeutics |
|
888 605 |
|
(60 979) |
|
USD |
|
65.35 |
|
57.3 |
|
1.9% |
|
2.1% |
|
1.1% |
|
Celldex Therapeutics |
|
1 800 000 |
|
1 800 000 |
|
USD |
|
28.11 |
|
49.9 |
|
1.6% |
|
1.8% |
|
3.8% |
|
Exelixis |
|
2 654 500 |
|
(180 500) |
|
USD |
|
15.68 |
|
41.1 |
|
1.4% |
|
1.5% |
|
0.8% |
|
Esperion Therapeutics |
|
4 194 064 |
|
(283 900) |
|
USD |
|
6.70 |
|
27.7 |
|
0.9% |
|
1.0% |
|
6.3% |
|
Beam Therapeutics |
|
568 121 |
|
(38 700) |
|
USD |
|
47.64 |
|
26.7 |
|
0.9% |
|
1.0% |
|
0.8% |
|
Mersana Therapeutics |
|
3 866 200 |
|
(268 800) |
|
USD |
|
6.76 |
|
25.8 |
|
0.9% |
|
0.9% |
|
4.0% |
|
Kezar Life Sciences |
|
3 000 000 |
|
(1 918 148) |
|
USD |
|
8.61 |
|
25.5 |
|
0.8% |
|
0.9% |
|
4.4% |
|
Macrogenics |
|
7 275 564 |
|
– |
|
USD |
|
3.46 |
|
24.8 |
|
0.8% |
|
0.9% |
|
11.8% |
|
Generation Bio Co. |
|
3 608 280 |
|
(244 900) |
|
USD |
|
5.31 |
|
18.9 |
|
0.6% |
|
0.7% |
|
6.1% |
|
Rivus Pharmaceuticals 1) |
|
|
|
|
|
USD |
|
|
|
17.3 |
|
0.6% |
|
0.6% |
|
|
|
Wave Life Sciences |
|
4 494 458 |
|
(108 400) |
|
USD |
|
3.61 |
|
16.0 |
|
0.5% |
|
0.6% |
|
5.2% |
|
Scholar Rock Holding |
|
2 132 725 |
|
(142 400) |
|
USD |
|
6.93 |
|
14.6 |
|
0.5% |
|
0.5% |
|
4.1% |
|
Essa Pharma |
|
5 879 583 |
|
863 769 |
|
USD |
|
1.82 |
|
10.6 |
|
0.4% |
|
0.4% |
|
13.3% |
|
Molecular Templates |
|
11 192 003 |
|
400 000 |
|
USD |
|
0.75 |
|
8.3 |
|
0.3% |
|
0.3% |
|
19.9% |
|
Black Diamond Therapeutics |
|
4 694 113 |
|
1 254 113 |
|
USD |
|
1.69 |
|
7.8 |
|
0.3% |
|
0.3% |
|
12.9% |
|
Homology Medicines |
|
1 622 522 |
|
(114 600) |
|
USD |
|
1.61 |
|
2.6 |
|
0.1% |
|
0.1% |
|
2.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Radius Health – Contingent Value Right |
|
8 733 538 |
|
8 733 538 |
|
USD |
|
0.00 |
|
0.0 |
|
0.0% |
|
0.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
3 025.0 |
|
100.0% |
|
111.2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
3.1 |
|
|
|
0.1% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(306.9) |
|
|
|
(11.3%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
2 721.3 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1) Unlisted company
Exchange rate as at 30.09.2022: USD/CHF: 0.9870